Evidence map›Paper›PMID 26675742›Full record

ArticleThe oncologist2016

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

Johanna Wassermann, Marie-Odile Bernier, Jean-Philippe Spano, Charlotte Lepoutre-Lussey, Camille Buffet, Jean-Marc Simon, Fabrice Ménégaux, Frédérique Tissier, Monique Leban, Laurence Leenhardt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Clinico-pathological factors and [BMC medical imaging · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johanna WassermannDepartment of Medical Oncology, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France Thyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Marie-Odile BernierThyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France Department of Epidemiology, Institute of Nuclear safety and radioprotection, Fontenay aux Roses, France.
Jean-Philippe SpanoDepartment of Medical Oncology, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Charlotte Lepoutre-LusseyThyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Camille BuffetThyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Jean-Marc SimonDepartment of Radiotherapy, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Fabrice MénégauxDepartment of Endocrine Surgery, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Frédérique TissierDepartment of Pathology, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Monique LebanDepartment of Biochemistry, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France.
Laurence LeenhardtThyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Paris, France laurence.leenhardt@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOutcomes vary among patients with radioiodine refractory (RR) differentiated thyroid cancer (DTC). The prognostic factors for survival are not well-known, resulting in difficulty in selecting patients for new targeted therapies. We assessed overall survival (OS) and cancer-specific survival (CSS) from RR-DTC to identify prognostic factors associated with survival. PATIENTS AND

methodsThe data on all cases of metastatic RR-DTC treated in our center from 1990 to 2011 were retrospectively reviewed. Survival was estimated using the Kaplan-Meier method; associated prognostic factors were assessed using Cox's model.

resultsOf 153 cases of metastatic DTC, 59% (n = 91) met a criterion for RR: that is, 60% (n = 55) had at least 1 metastasis without (131)I uptake; 21% (n = 19) had progressive disease (PD) despite (131)I; 19% (n = 17) had persistent disease despite a cumulative activity of (131)I of ≥600 mCi. After the diagnosis of RR, median OS was 8.9 years (95% confidence interval [CI]: 5.4-NR); median CSS was 9.6 years (95% CI: 6.01-NR). In multivariate analyses, PD despite (131)I as a criterion for RR disease and the time from initial diagnosis of DTC to diagnosis of RR <3 years were the only independent prognostic factors for poor OS and CSS. Thyroglobulin doubling time (Tg-DT) was assessed in 31 of 91 cases. Among the 11 patients with Tg-DT for <1 year or undetectable Tg, 6 deaths occurred, whereas only 3 died of 20 patients with Tg-DT >1 year or negative Tg-DT.

conclusionThe identification of prognostic factors for decreased survival in RR-DTC may improve the selection of patients for targeted agents. IMPLICATIONS FOR PRACTICE: This study shows a great heterogeneity in terms of prognosis in radioiodine refractory differentiated thyroid carcinoma. Poorer prognosis is observed in patients with tumor progression or with a diagnosis of radioiodine resistance within 3 years after the initial diagnosis of thyroid cancer. Those findings could lead to improvements in the selection of patients for targeted therapies.

Indexed as

Molecular Targeted TherapyRadiation ToleranceAdenocarcinomaAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansIodine RadioisotopesKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesThyroglobulinIodine RadioisotopesThyroglobulinIodine radioisotopesMolecular targeted therapySurvival analysisThyroglobulinThyroid neoplasm

Identifiers

PMID26675742
PMCPMC4709201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.